EUVIMEDEUVIMED entdecken
Crossref

Gap Between Estimated Need and Observed Uptake of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Among Patients With Lung Cancer in Indonesia

Oke Dimas Asmara iD, Eric Daniel Tenda iD, Fahmi Radityamurti iD, Ni Nyoman Indirawati, I Putu Eka Krisnha Wijaya, Hadiki Habib, Herikurniawan Herikurniawan, Mira Yulianti, Gurmeet Singh iD, Telly Kamelia, Ceva Wicaksono Pitoyo, C Martin Rumende und 10 weitere

JCO Global Oncology · 2026

DOI: 10.1200/go-26-00210 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Global Oncology, 2026. Verfasst von Oke Dimas Asmara und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Respirology and Critical Illness, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Dr Cipto Mangunkusumo Nati…. Hauptthemen laut MEDLINE: Lung Neoplasms, Protein Kinase Inhibitors. Die Arbeit nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

In many low- and middle-income countries, access to molecularly targeted therapies for lung cancer remains limited. This study assessed the gap between estimated epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment need and observed uptake in Indonesia and evaluated the gap before and after implementation of the National Reimbursement System (NRS). We hypothesized that many potentially eligible patients in Indonesia would not receive EGFR-TKI therapy, as they ideally should.

Methods

We retrospectively analyzed all patient cases of lung cancer registered between 2008 and 2020 at Indonesia's national referral hospital. Patients with a registered diagnosis verified by histopathology or supporting clinical evidence were included. Because patient-level molecular and clinical eligibility data were incomplete, EGFR-TKI eligibility was estimated using a stepwise epidemiologic model. A model-based sensitivity analysis was performed to assess robustness. Observed uptake was compared before and after NRS implementation.

Results

A total of 1,426 patients with lung cancer were included; 67.8% were male; the median age was 55 years for men and 53 years for women. Of those with known stage and histology, 93.6% were stage IV; adenocarcinoma accounted for 57.2% of patients with non–small cell lung cancer. Under lower-bound, primary, and upper-bound models, estimated eligible populations were 128 (9.0%), 226 (15.8%), and 378 (26.5%) patients, respectively. Only 41 patients received EGFR-TKIs, corresponding to 32.0%, 18.1%, and 10.8% of the estimated eligible population, respectively. After NRS implementation, uptake increased from 0% to 25.0% of the primary estimate; however, a substantial gap persisted throughout the study period.

Conclusion

Despite national reimbursement, EGFR-TKI uptake remained substantially below the estimated need even under the most conservative model. Persistent barriers that span diagnostics, infrastructure, and financing are likely to contribute. Coordinated strategies beyond formulary listings are required to improve access to EGFR-TKI therapy in middle-income settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsProtein Kinase InhibitorsHumansFemaleMaleIndonesiaMiddle AgedErbB ReceptorsRetrospective StudiesAgedAdultCarcinoma, Non-Small-Cell Lung

Substanzen

Protein Kinase InhibitorsErbB ReceptorsEGFR protein, human

Autor:innen und Institutionen

  • Division of Respirology and Critical Illness, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Dr Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia.
  • Department of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Faculty Campus Fryslán, University of Groningen, Leeuwarden, the Netherlands.
  • Department of Pulmonary Medicine, Frisius Medical Center, Leeuwarden, the Netherlands.
  • Department of Radiation Oncology, Faculty of Medicine Universitas Indonesia, Dr Cipto Mangunkusumo General Hospital, Jakarta, Indonesia.
  • Department of Pulmonology and Respiratory Medicine, Persahabatan Hospital, Jakarta, Indonesia.

ORCID-Profile: Oke Dimas Asmara, Eric Daniel Tenda, Fahmi Radityamurti, Gurmeet Singh, Anggriyani Wahyu Pinandari, Yayi Dwina Billianti Susanto, Lisnawati Rachmadi, Andhika Rachman, Aru W Sudoyo, E Christiaan Boerma, Soehartati A Gondhowiardjo, Wouter H van Geffen

Zitieren

APA

Asmara, O. D., Tenda, E. D., Radityamurti, F., Indirawati, N. N., Wijaya, I. P. E. K., Habib, H., Herikurniawan, H., Yulianti, M., Singh, G., Kamelia, T., Pitoyo, C. W., Rumende, C. M., Amin, Z., Pinandari, A. W., Susanto, Y. D. B., Rachmadi, L., Rajabto, W., Rachman, A., Sudoyo, A. W., …, & van Geffen, W. H. (2026). Gap Between Estimated Need and Observed Uptake of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Among Patients With Lung Cancer in Indonesia. JCO Global Oncology. https://doi.org/10.1200/go-26-00210

Vancouver

Asmara OD, Tenda ED, Radityamurti F, Indirawati NN, Wijaya IPEK, Habib H, et al. Gap Between Estimated Need and Observed Uptake of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Among Patients With Lung Cancer in Indonesia. JCO Global Oncology. 2026. doi:10.1200/go-26-00210

BibTeX
@article{Asmara2026,
  author = {Asmara, Oke Dimas and Tenda, Eric Daniel and Radityamurti, Fahmi and Indirawati, Ni Nyoman and Wijaya, I Putu Eka Krisnha and Habib, Hadiki and Herikurniawan, Herikurniawan and Yulianti, Mira and Singh, Gurmeet and Kamelia, Telly and Pitoyo, Ceva Wicaksono and Rumende, C Martin and Amin, Zulkifli and Pinandari, Anggriyani Wahyu and Susanto, Yayi Dwina Billianti and Rachmadi, Lisnawati and Rajabto, Wulyo and Rachman, Andhika and Sudoyo, Aru W and Boerma, E Christiaan and Gondhowiardjo, Soehartati A and van Geffen, Wouter H},
  title = {Gap Between Estimated Need and Observed Uptake of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Among Patients With Lung Cancer in Indonesia},
  journal = {JCO Global Oncology},
  year = {2026},
  doi = {10.1200/go-26-00210}
}
Kostenlos starten →